The pharmacokinetics of the newly developed anti-herpes agent, E-5-(2-bromovinyl)-2'-deoxyuridine, was compared with that of the standard anti-herpes drug 5-iodo-2'-deoxyuridine. Both compounds were administered to mice at 100 mg/kg by either the intraperitoneal, subcutaneous, or oral route. The active blood drug levels achieved by E-5-(2-bromovinyl)-2'-deoxyuridine were considerably higher than those attained by 5-iodo-2'-deoxyuridine (serum peak concentrations: 40 to 100 and 4 to 10 μg/ml, respectively). Active blood drug levels could still be found 320 min after oral administration of E-5-(2-bromovinyl)-2'-deoxyuridine.
引用
收藏
页码:234 / 236
页数:3
相关论文
共 4 条
[1]
Bauer DJ, 1977, SPECIFIC TREATMENT V
[2]
DECLERCQ E, 1979, P NATL ACAD SCI USA, V76, P2947, DOI 10.1073/pnas.76.6.2947